Abstract
Introduction
Warm autoimmune hemolytic anemia (AIHA) is the most prevalent type of AIHA and is characterized by the destruction of red blood cells by warm autoantibodies optimally reactive at 37°C1. Current therapeutic interventions for warm AIHA include corticosteroids,
rituximab, and surgical splenectomy. Many patients, however, cannot be treated with these therapies and may experience severe side effects2. In order to provide effective and definitive therapy for patients with primary warm AIHA, close collaboration between clinicians and laboratories may be needed3. Here, we describe how appropriate and timely laboratory practices led to proper therapeutic management, particularly when combined with the prompt recognition of the patient as a regular repeat blood donor.
Downloads
- Abstract viewed - 526 times
- pdf downloaded - 188 times